Association of Birth Weight With Type 2 Diabetes and Glycemic Traits
A Mendelian Randomization Study

BIRTH-GENE (BIG) Study Working Group

Abstract

IMPORTANCE Observational studies have shown associations of birth weight with type 2 diabetes (T2D) and glycemic traits, but it remains unclear whether these associations represent causal associations.

OBJECTIVE To test the association of birth weight with T2D and glycemic traits using a mendelian randomization analysis.

DESIGN, SETTING, AND PARTICIPANTS This mendelian randomization study used a genetic risk score for birth weight that was constructed with 7 genome-wide significant single-nucleotide polymorphisms. The associations of this score with birth weight and T2D were tested in a mendelian randomization analysis using study-level data. The association of birth weight with T2D was tested using both study-level data (7 single-nucleotide polymorphisms were used as an instrumental variable) and summary-level data from the consortia (43 single-nucleotide polymorphisms were used as an instrumental variable). Data from 180,056 participants from 49 studies were included.

MAIN OUTCOMES AND MEASURES Type 2 diabetes and glycemic traits.

RESULTS This mendelian randomization analysis included 49 studies with 41,155 patients with T2D and 80,008 control participants from study-level data and 34,840 patients with T2D and 114,981 control participants from summary-level data. Study-level data showed that a 1-SD decrease in birth weight due to the genetic risk score was associated with higher risk of T2D among all participants (odds ratio [OR], 2.10; 95% CI, 1.69-2.61; \( P = 4.03 \times 10^{-5} \)), among European participants (OR, 1.96; 95% CI, 1.42-2.71; \( P = .04 \), and among East Asian participants (OR, 1.39; 95% CI, 1.18-1.62; \( P = .04 \)). Similar results were observed from summary-level analyses. In addition, each 1-SD lower birth weight was associated with a 0.189 SD increase in fasting glucose concentration (\( \beta = 0.189; SE = 0.060; P = .002 \)), but not with fasting insulin, 2-hour glucose, or hemoglobin A1c level.

CONCLUSIONS AND RELEVANCE In this study, a genetic predisposition to lower birth weight was associated with increased risk of T2D and increased fasting glucose concentration, suggesting genetic effects on retarded fetal growth and increased diabetes risk that either are independent of each other or operate through alterations of integrated biological mechanisms.

Key Points

Question Is birth weight associated with type 2 diabetes and glycemic traits?

Findings This mendelian randomization study found that a 1-SD decrease in birth weight due to the genetic risk score was associated with a higher risk of type 2 diabetes among European and East Asian populations. In addition, a 1-SD decrease in birth weight was associated with a 0.189-SD increase in fasting glucose concentration, but not with fasting insulin, 2-hour glucose, or hemoglobin A1c level.

Meaning A genetic predisposition to lower birth weight was associated with an increased risk of type 2 diabetes and increased fasting glucose, suggesting potential mechanisms through which perturbation of the antenatal and early-life environment affect predisposition to diabetes in later life.

Introduction

Type 2 diabetes (T2D) has become a worldwide epidemic, with more than 422 million patients in 2014. However, the etiology of T2D is not fully understood. Identifying potentially causal risk factors would help guide prevention of the disease.

Open Access. This is an open access article distributed under the terms of the CC-BY License.
The thrifty phenotype hypothesis postulates that fetal growth and nutrition play important roles in influencing susceptibility to T2D in later life. In observational studies, low birth weight, a widely used indicator for fetal growth restriction, has been consistently associated with higher risk of T2D and adverse glycemic traits in later life. However, both maternal socioeconomic status and unmeasured lifestyle factors might confound these associations; therefore, the causality of these observations remains to be determined. We hypothesized that birth weight may be causally associated with T2D risk and related traits such as fasting glucose concentration, insulin level, insulin resistance, and insulin sensitivity.

Mendelian randomization (MR) analysis has become widely used to assess the potential causal associations of environmental risk factors with disease. This method is analogous to a randomized clinical trial where randomization to genotype takes place at conception, and it is less likely to be affected by confounding and reverse causation. Previous analyses have provided compelling evidence that fetal genotype has substantial impact on early growth, as measured by birth weight.

Therefore, in this study, we used the genetic variants for birth weight as an instrumental variable to perform an MR analysis to examine the association of birth weight with T2D and glycemic traits, using both study-level data and summary-level data.

Methods

Study Design

This study was conducted using summary association data generated by previous studies. Owing to the use of previously collected, deidentified, aggregated data, this study did not require institutional review board approval per the US Federal Policy for Protection of Human Research Subjects. Ethical approval was obtained for all original studies. Reporting of this study followed the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) reporting guideline.

Observational studies are prone to reverse causation, confounding, and biases and can generate unreliable findings in relation to the causal effects of modifiable exposures on disease outcomes. Mendelian randomization is a method aimed at unbiased detection of causal effects and estimation of their magnitudes (eMethods in the Supplement). To consistently estimate the causal effects, the genetic variants used in an MR analysis must satisfy 3 assumptions (eFigure 1 in the Supplement): (1) the genetic variants used as instrumental variables (IV) are associated with the exposure (birth weight); (2) the genetic variants are not associated with any confounder of the exposure-outcome association; and (3) the genetic variants are conditionally independent of the outcome (T2D and glycemic traits) given the exposure and confounders. The second and third assumptions are known as independence from pleiotropy.

The study design of this MR analysis consisted of 2 components (Figure 1). First, we explored the association of birth weight with risk of T2D using study-level data, including 49 cross-sectional and prospective cohort studies with a total of 180,056 participants, including 41,155 patients with T2D from the Cohorts for Heart and Aging Research in Genomic Epidemiology—Birth Gene Study (CHARGE-BIG). The primary IV was a genetic risk score (GRS) for birth weight using 7 single-nucleotide polymorphisms (SNPs) ($P < 5 \times 10^{-8}$) from a genome-wide association study (GWAS) in the Early Growth Genetics (EGG) Consortium. We analyzed the data within each study using standardized analytic methods. The IV estimator is calculated as the pooled coefficient from the GRS-T2D association divided by the pooled coefficient from the GRS–birth weight association.

Second, we tested the association of birth weight with T2D and glycemic traits using summary-level data from the EGG Consortium (n = 153,781), the Diabetes Genetics Replication and Meta-analysis (DIAGRAM) Consortium (n = 149,821), and the Meta-analyses of Glucose and Insulin-Related Traits (MAGIC) Consortium (n = 133,010). In this study, the 7-SNP score was used as the main IV because the new GWAS that identified 60 SNPs for birth weight was published after the study-level results had already been run. Therefore, we used the 43 SNPs available in this analysis, a subset of the 60 SNPs, as the IV for birth weight in summary-level analyses.
Study Populations and Data Sources

Study-Level Data

Study-level data including 49 cross-sectional and prospective cohort studies with up to 180,056 participants from the CHARGE-BIG were used (eTable 1 in the Supplement). Descriptions of each participating study are shown in the eAppendix in the Supplement. All participants provided written, informed consent, and ethical approval was granted by local ethics committees for participating studies (eTable 2 in the Supplement). Birth weight was collected by self-reported questionnaires or medical records in each study. Detailed information on the study-specific data collection methods is provided in eTable 2 in the Supplement. Covariates were measured using direct measurement or self-reported using questionnaire data from each study (eTable 2 in the Supplement). The primary outcomes were prevalence or incidence of T2D, defined based on report of T2D or current use of antidiabetes medication. Participants with missing values or those lost to follow-up were excluded. Precise information on the outcome for each study is reported in eTable 3 in the Supplement.

Selection of SNPs and GRS Calculation

Seven SNPs were identified as being associated with birth weight by a previous GWAS. All studies used direct genotype information on SNPs for birth weight from previously genotyped array data. Whenever a SNP was not genotyped directly, we used either (1) the HapMap II CEU (European) reference panel-imputed genetic information from GWAS or (2) genotype information from a predefined list of proxies that are in high linkage disequilibrium with the SNP ($r^2 > 0.8$). Genotyping platforms, genotype frequencies, Hardy-Weinberg equilibrium $P$ values, and call rates for the 7 SNPs are listed in eTable 4 and eTable 5 in the Supplement. To estimate the genetic predisposition to low birth weight, a GRS for low birth weight was calculated on the basis of these 7 well-established SNPs (eTable 6 in the Supplement). We assumed that each SNP in the panel acts independently in an additive manner, and the GRS was calculated using a weighted method (eAppendix in the Supplement).

Summary-Level Data

Summary-level data from the EGG Consortium, DIAGRAM Consortium, and MAGIC Consortium were used. For IV, both the 7-SNP GRS (explained between 0.32% and 1.52% of variance in birth weight) (eTable 6 and eTable 7 in the Supplement) and the 43-SNP GRS (explained 2.0% of variance in birth weight) (eTable 8 and eTable 9 in the Supplement) for birth weight were

Figure 1. Study Design

Sources of data for analysis included study-level data from the Cohorts for Heart and Aging Research in Genomic Epidemiology Birth Gene (CHARGE-BIG) Study (49 studies, n = 180,056 participants) and summary-level data from the Diabetes Genetics Replication and Meta-analysis (DIAGRAM) Consortium (n = 149,821 participants), the Meta-analyses of Glucose and Insulin-Related Traits (MAGIC) Consortium (n = 133,010 participants), and the Early Growth Genetics (EGG) Consortium (n = 153,781 participants). $HbA_1c$ indicates hemoglobin $A_1c$, and SNP, single-nucleotide polymorphism.

a Estimates of 7 SNPs for birth weight were extracted from the EGG Consortium (n = 69,308 participants).23

b Estimates of 43 SNPs for birth weight were extracted from the EGG Consortium (n = 153,781 participants).13
used from 2 previous GWAS studies in the EGG Consortium with up to 153,781 individuals. For T2D, data were obtained from the DIAGRAM Consortium; this study included 149,821 individuals of European descent. In addition to the primary outcomes of T2D, secondary outcomes of glycemic traits such as fasting glucose, fasting insulin, 2-hour glucose, and hemoglobin A1c concentrations were examined (eTable 7 and eTable 9 in the Supplement). Data from the MAGIC Consortium with up to 133,010 individuals were used for glycemic traits. Informed consent was obtained from all participants of contributing studies. Contributing studies received ethical approval from their respective institutional review boards.

**Statistical Analysis**

**Study-Level Data**

For study-level data from the CHARGE-BIG study, a standard analytic protocol was applied to each individual study to produce comparable results. Logistic regression was used to test the association of birth weight with risk of T2D after adjustment for age, sex, and other baseline covariates, where available (smoking status, physical activity, total energy intake, and alcohol intake). Linear regression was used to test the association of the GRS with birth weight after adjustment for age, sex, and principal components for population stratification (principal components analysis [PCA]). Logistic regression was used to test the association of the GRS with risk of T2D after adjustment for age, sex, and PCA. The inclusion of PCA as covariates is commonly used to correct for population stratification according to ancestral background.

To validate assumption 1, that the GRS for birth weight was a strong IV for birth weight (eTable 10 in the Supplement), an $F$ statistic for the IV was calculated in the Nurses’ Health Study (NHS) and Health Professionals Follow-up Study (HPFS) cohorts as a measure of the strength of IV for prediction of the birth weight, controlling for covariates (age, sex, PCA). An $F$ statistic greater than 10 is evidence of a strong IV.

To examine assumption 2, that GRS for birth weight was not associated with potential confounders, the association of the GRS with age, body mass index, smoking, alcohol use, and total energy intake was determined among individuals in the NHS and HPFS cohorts (eTable 11 in the Supplement).

Meta-analyses were conducted using study-level data from each study: we then pooled the $\beta$ coefficients across studies, using random-effects or fixed-effects meta-analysis. Meta-analyses were conducted in Stata statistical software version 13.0 (StataCorp). All $P$ values reported are 2-sided. We assessed heterogeneity with the $I^2$ statistic. We assessed between-study heterogeneity via the Cochran Q statistic and $I^2$ statistics. For the proposed cutoff of $I^2 > 0.25$, we found nonnegligible heterogeneity between studies, in particular among the birth weight-T2D associations, but also for the association between GRS and birth weight or T2D ($I^2 > 0.25$). As a consequence, we used random-effects meta-analysis throughout. After meta-analysis, we used the IV estimators to quantify the strength of the association of birth weight with risk of T2D. The IV estimator, which is identical to that derived by the widely used 2-stage least-squares method, was calculated as the $\beta$ of the regression coefficients for GRS-T2D and GRS–birth weight associations (eMethods in the Supplement).

**Summary-Level Data**

For the summary-level data from the EGG, DIAGRAM, and MAGIC consortia, the estimates of the association of birth weight with T2D risk and glycemic traits were pooled using the inverse-variance weighted, MR-Egger, and weighted-median methods for multiple genetic variants (eMethods in the Supplement). Detailed information on this MR method has been described previously.

To examine assumption 3, that the IV for birth weight affects risk of T2D only through birth weight, but not through other pathways, the MR-Egger method was used (eMethods in the Supplement). Egger regression is a tool to detect small study bias in meta-analysis and it can be adapted to test for bias from type I pleiotropy, which is problematic for the interpretation of MR. Type
Ipleiotropyoccurs when a single locus directly influences multiple phenotypes and is more pronounced at the level of the gene than at the level of single SNPs. Under the assumption that the association of each genetic variant with the exposure is independent of the pleiotropic effect of the variant (not via the exposure), the MR-Egger test gives a valid test of the null causal hypothesis. Using the MR-Egger method, the effect of the IV on the exposure is plotted against its effect on the outcome, and an intercept distinct from the origin provides evidence for pleiotropic effects. Additionally, the slope of the MR-Egger can provide pleiotropy-corrected causal estimates under a weaker assumption (the instrument strength independent of direct effect assumption).

For analyses of both study-level data and summary-level data, the effect size for each meta-analysis is reported in the main results as the effect of a 1-SD change in birth weight or glycemic quantitative traits, as this metric is more interpretable than an arbitrary difference. Absolute risk increase (ARI) per 1000 participant-years for T2D was also calculated (eMethods in the Supplement). 
P < .05 was considered statistically significant. Analyses were performed using Stata statistical software version 13 (StataCorp) and R statistical software version 3.2.3 (R Project for Statistical Computing).

Results

Characteristics of the 49 Participating Studies
The characteristics of the 49 participating studies with up to 180,056 participants, including 41,155 patients with T2D, are presented in eTable 1 in the Supplement. Twenty-two studies reported the genetic association between GRS and birth weight, and 33 studies reported the genetic association between GRS and risk of T2D. A total of 41,155 patients with T2D and 80,008 control individuals without T2D provided study-level data. Data from the DIAGRAM Consortium included 34,840 patients with T2D and 114,981 control individuals, overwhelmingly of European descent. The MAGIC Consortium included 133,010 participants, and the EGG Consortium included 153,781 participants (Figure 1).

Results for Testing MR Assumptions
To validate MR assumptions 1 and 2, the NHS and HPFS cohorts were used to examine the associations of GRS with birth weight and potential confounders. We found that the GRS for birth weight was a strong IV (F > 18) (eTable 10 in the Supplement), thus validating assumption 1. In addition, no associations between the GRS and age, body mass index, smoking, alcohol use, and total energy intake were observed in the NHS and HPFS cohorts (eTable 11 in the Supplement), thus validating assumption 2.

Association of Birth Weight With Risk of T2D
Study-level data showed that each 1-SD decrease in birth weight due to the GRS was associated with higher risk of T2D among all participants (odds ratio [OR], 2.10; 95% CI, 1.69-2.61; and ARI per 1000 participant-years, 8.9; 95% CI, 0.2-9.0; P = 4.03 × 10⁻⁵), among European participants (OR, 1.96; 95% CI, 1.42-2.71; and ARI per 1000 participant-years, 7.48; 95% CI, 3.27-13.34; P = .04) (Table 1), and among East Asian participants (OR, 1.39; 95% CI, 1.18-1.62; and ARI per 1000 participant-years, 3.04; 95% CI, 1.40-4.84; P = .04) (Figure 2; eFigure 2 and eFigure 3 in the Supplement). We did not find a significant difference in OR for T2D between MR estimates and conventional observational results (OR, 1.41 per 1-SD lower birth weight; 95% CI, 1.16-1.66) from 11 studies of the CHARGE-BIG (P = .86) (eFigure 4 in the Supplement).

We further conducted stratified analyses of estimated causality by age, sex, body mass index, ethnic group, sample size, study design, and number of SNPs included. An association of birth weight with T2D was observed among both men and women, both obese and normal-weight participants, and both European and East Asian participants. However, evidence for a causal association was not observed in the subsample of individuals younger than 50 years (Table 2).
Summary-level data showed a similar association of low birthweight with risk of T2D when using the 7 SNPs (OR, 2.79; 95% CI, 1.90-4.20; and ARI per 1000 participant-years, 13.96; 95% CI, 7.02-24.96; and P = .02) and when using 43 SNPs (OR, 1.86; 95% CI, 1.07-3.60; and ARI per 1000 participant-years, 6.70; 95% CI, 0.55-20.28; P = .03) (Figure 2). We further excluded previously reported loci for T2D such as CDKAL1, ADCY5, BCAR1, HHEX/IDE, GCK, MTNR1B, and ANK1, and low birthweight remained associated with risk of T2D (OR, 1.75; 95% CI, 1.05-3.16; P = .04).

Association of Birth Weight With Glycemic Quantitative Traits
Using the weighted median–based method, we found that a 1-SD lower birthweight due to the GRS was associated with 0.189 SD higher fasting glucose concentration (β = 0.189; SE = 0.060; P = .002) at the Bonferroni-adjusted level of significance (P < .01). Consistently, the inverse-variance–weighted analysis also showed an association of birthweight with fasting glucose concentration.

### Table 1. Mendelian Randomization of Birth Weight and Risk of Type 2 Diabetes

| MR Estimatesa | Summary Data Ab | Summary Data Bb |
|---------------|-----------------|-----------------|
|               | OR (95% CI)     | P Value         | OR (95% CI)     | P Value         |
| Simple median-based methodc | 1.57(1.24 to 2.00) | 2.0 × 10-4 | 1.24(1.09 to 1.41) | .001 |
| Weighted median-based methodc | 1.52(1.24 to 1.86) | 1.1 × 10-4 | 1.29(1.13 to 1.47) | 6.0 × 10-4 |
| Inverse-variance–weighted methodc | 1.69(1.12 to 2.55) | .045 | 1.36(1.14 to 1.62) | .001 |
| MR-Egger methodc | 2.79(1.90 to 4.20) | .02 | 1.96(1.07 to 3.60) | .03 |
| MR-Egger regressiond | 0.007 (~0.081 to 0.095) | .94 | 0.011 (~0.002 to 0.02) | .22 |

Abbreviations: MR, mendelian randomization; OR, odds ratio.

a In an MR framework, genetic variants for birth weight were assumed to influence type 2 diabetes only through birth weight, not through other pathways. In the present study, we used MR-Egger regression to assess for the presence of pleiotropy.16 This approach is based on Egger regression, which was used to assess publication bias in the meta-analysis.34 Using the MR-Egger method, the β coefficient of the MR-Egger regression provides pleiotropy-corrected causal estimates and an intercept distinct from the origin provides evidence for pleiotropic effects.35

b Sample sizes of patients with type 2 diabetes and control individuals were 12,717 and 568,922 for both summary data A and summary data B. Number of single-nucleotide polymorphisms used of summary data A and summary data B are 7 and 43, respectively. Number of participants with birth weight in summary data A and summary data B are 69,308 and 153,781, respectively.

c We used simple median-based method, weighted median-based method, inverse-variance-weighted method, and MR-Egger method to provide consistent results for causal effect of birth weight on type 2 diabetes.

d Values in this row are intercept (95% CI).

### Figure 2. Mendelian Randomization of Birth Weight and Risk of Type 2 Diabetes (T2D)

For type 2 diabetes, the data were analyzed from 49 studies from the Cohorts for Heart and Aging Research in Genomic Epidemiology Birth Gene Study where standardized analytic methods were used in individual study. This study included 41,155 participants with T2D and 80,008 controls. Data from the Diabetes Genetics Replication and Meta-analysis (DIAGRAM) Consortium included 34,840 patients with T2D and 114,981 controls, overwhelmingly of European descent. Summary results of 7 single-nucleotide polymorphisms (SNPs) for birth weight identified in genome-wide association studies were extracted from the Early Growth Genetics Consortium.23 Summary results for risk of T2D were extracted from the DIAGRAM Consortium.17 Summary results of 43 SNPs for birth weight were extracted from the Early Growth Genetics birth weight genome-wide association study.17 Summary results for risk of T2D were extracted from the DIAGRAM Consortium.17 We used the standard deviation value (543 g) from the birth weight genome-wide association study of the EGG Consortium.17 Results are standardized to a 1-SD lower birth weight owing to genetic risk score. ARI indicates absolute risk increase; OR, odds ratio.
(0.207 SD higher fasting glucose concentration per 1-SD lower birth weight; $\beta = 0.207; SE = 0.073; P = .03$) (Table 3). These findings were replicated using the 43 SNPs as an IV, suggesting robustness of our findings. However, there was no evidence for an association of birth weight with other glycemic traits such as fasting insulin, 2-hour glucose, or hemoglobin $A_1c$ concentrations (Table 3).

**Sensitivity Analyses of MR**

In sensitivity analyses, we used 4 different methods (simple median based, weighted median based, inverse-variance weighted, and MR-Egger) to estimate the association of birth weight with risk of T2D using summary-level data. The results showed consistent associations (Table 2), indicating robustness of our findings. We further conducted a sensitivity analysis of association of birth weight with risk of T2D using 8 studies providing both GRS-birth weight and GRS-T2D associations (Supplement in the CHARGE-BIG study). Similarly, we found that each 1-SD lower birth weight due to the GRS was associated with higher risk of T2D (OR, 2.66; 95% CI, 1.30-4.02; $P = 6.76 \times 10^{-4}$), providing further evidence of finding robustness.

To examine MR assumption 3, we further tested whether any of the selected SNPs were influenced by linkage disequilibrium and pleiotropy. We found that none of the SNPs were in linkage disequilibrium with each other ($r^2 > 0.05$). In addition, the intercept term estimated from MR-Egger was centered at the origin with a confidence interval including the null (0.007; 95% CI $-0.081$ to $0.095; P = .94$) (Table 1), suggesting the results were not influenced by pleiotropy.

**Table 2. Stratified Analyses of Estimated Causality Between Birth Weight and Risk of Type 2 Diabetes**

| Subgroup                  | Genetic Association of Birth Weight per SD$^a$ | Genetic Association of Type 2 Diabetes | Estimated Causality$^a$ |
|---------------------------|-----------------------------------------------|---------------------------------------|------------------------|
|                           | No. of Studies | $\beta$ (95% CI) | $P$ Value | No. of Studies | $\beta$ (95% CI) | $P$ Value | OR (95% CI) | $P$ Value |
| Age, y                    |                |                  |          |                |                  |          |            |          |
| $\geq 50$                 | 23             | 0.04 (0.03 to 0.05) | $3.6 \times 10^{-4}$ | 28            | 0.03 (0.01 to 0.05) | 0.004    | 2.12 (1.70 to 2.64) | 0.006    |
| $<50$                     |                |                  |          | 5             | 0.04 (-0.10 to 0.02) | .18      | 1.67 (0.87 to 5.65) | .18      |
| Sex                       |                |                  |          |                |                  |          |            |          |
| Male                      | 17             | 0.04 (0.02 to 0.05) | $8.4 \times 10^{-4}$ | 24            | 0.03 (0.01 to 0.05) | .006    | 1.89 (1.46 to 2.46) | .02      |
| Female                    | 16             | 0.04 (0.01 to 0.06) | $9.4 \times 10^{-4}$ | 23            | 0.03 (0.01 to 0.04) | .002    | 2.10 (1.49 to 2.97) | .03      |
| Body mass index$^c$       | 23             | 0.04 (0.03 to 0.05) | $3.6 \times 10^{-4}$ | 25            | 0.02 (0.00 to 0.04) | .02     | 1.81 (1.39 to 2.37) | .03      |
| $\geq 25$                 |                |                  |          | 8             | 0.04 (0.02 to 0.06) | <.001   | 2.82 (2.20 to 3.60) | $3.1 \times 10^{-5}$ |
| $<25$                     |                |                  |          |                |                  |          |            |          |
| Ethnic group              |                |                  |          |                |                  |          |            |          |
| European                  | 22             | 0.04 (0.03 to 0.05) | $3.6 \times 10^{-4}$ | 24            | 0.03 (0.01 to 0.05) | .02     | 1.96 (1.42 to 2.71) | .04      |
| East Asian                | 1              | 0.09 (0.00 to 0.18) | $5.1 \times 10^{-3}$ | 9             | 0.03 (0.02 to 0.04) | <.001   | 1.39 (1.18 to 1.62) | .04      |
| Sample size, No.          | 23             | 0.04 (0.03 to 0.05) | $3.6 \times 10^{-4}$ | 27            | 0.03 (0.01 to 0.04) | .001    | 1.96 (1.58 to 2.44) | .02      |
| $\geq 1500$               |                |                  |          | 6             | 0.07 (0.03 to 0.12) | <.001   | 3.45 (2.41 to 6.19) | .003     |
| $<1500$                   |                |                  |          |                |                  |          |            |          |
| Study design              | 23             | 0.04 (0.03 to 0.05) | $3.6 \times 10^{-4}$ | 26            | 0.03 (0.01 to 0.05) | <.001   | 2.06 (1.64 to 2.60) | .002     |
| Cohort                    |                |                  |          | 5             | 0.02 (-0.03 to 0.06) | .47     | 1.55 (0.85 to 2.84) | .47      |
| Case-control              |                |                  |          |                |                  |          |            |          |
| Cross-sectional           | 2              | 0.06 (-0.01 to 0.16) | .19 | 3.26 (0.89 to 7.02) | .19      |          |            |          |
| No. of single-nucleotide polymorphisms | 23 | 0.04 (0.03 to 0.05) | $3.6 \times 10^{-4}$ | 27            | 0.03 (0.01 to 0.05) | .003    | 2.17 (1.65 to 2.87) | .005     |
| $>7$                      |                |                  |          | 6             | 0.03 (0.01 to 0.04) | <.0004  | 1.91 (1.58 to 2.31) | .007     |

Abbreviation: OR, odds ratio.

$^a$ Results were standardized to a 1-SD decrease in birth weight due to genetic risk score. The standard deviation was 543 g from the Early Growth Genetics Consortium.13

$^b$ The estimates were derived from 49 studies from the Cohorts for Heart and Aging Research in Genomic Epidemiology Birth Gene Study where standardized analytic methods adjusted for confounders such as age, body mass index, sex, and the first 3 principal components for population stratification were used in individual study.

$^c$ Calculated as weight in kilograms divided by height in meters squared.
traits, the intercept (SE) from MR-Egger regression also suggested that the observed results were not influenced by pleiotropy (Table 3).

### Discussion

In the largest MR study thus far, to our knowledge, we investigated a potential causal role of birth weight in the development of T2D and regulation of glycemic traits using study-level data and summary-level data. Our results show that genetically determined lower birth weight was associated with increased risk of T2D and elevated fasting glucose concentration, supporting an association between lower birth weight and development of T2D.

Compelling observational studies have shown that lower birth weight is associated with a higher T2D risk.\(^3\)\(^4\)\(^35\)\(^40\) For example, data from a meta-analysis of 30 studies found an inverse birth weight-T2D association; the pooled OR of T2D was 1.13 (95% CI, 1.10-0.1.17) per kilogram decrease in birth weight.\(^3\) However, in most of the observational studies included in this meta-analysis, birth weight was associated with potential confounders. Therefore, residual confounding may have contributed to the observed associations, illustrating a major limitation of observational studies in inference of causality. In the present study, we used MR analysis to minimize the potential confounding effect. The GRS used in our study was not correlated with potential confounders, and was validated as a strong and reliable IV for birth weight.\(^35\) Therefore, our findings concur with a previous study\(^35\) and lend genetic support to prior evidence of observational association between birth weight and risk of T2D.

### Table 3. Mendelian Randomization Analyses of Birth Weight and Glycemic Quantitative Traits

| Data Source | SD | SNPs | Participants | MR-Egger Regression |
|-------------|----|------|--------------|---------------------|
|             |    |      |              | Intercept (SE) | P Value |
| Fasting glucose, mg/dL | 13.1 | 7 | 133 010 | 0.189 (0.060) | 0.027 (0.073) | 0.011 (0.341) | 0.005 (0.017) | 0.78 |
| Summary data A | 13.1 | 43 | 133 010 | 0.109 (0.049) | 0.415 (0.105) | 0.031 (0.099) | 0.018 (0.010) | 0.07 |
| Fasting insulin, log (pmol/L) | 0.44 | 7 | 108 557 | 0.089 (0.096) | 0.021 (0.108) | 0.131 (0.502) | 0.006 (0.026) | 0.82 |
| Summary data A | 0.44 | 43 | 108 557 | 0.033 (0.082) | 0.050 (0.060) | −0.027 (0.213) | 0.002 (0.006) | 0.70 |
| 2-h glucose, mg/dL | 10.1 | 7 | 42 854 | 0.494 (0.352) | 0.563 (0.411) | −0.584 (1.851) | 0.060 (0.094) | 0.52 |
| Summary data A | 10.1 | 43 | 42 854 | 0.406 (0.254) | 0.319 (0.203) | 0.378 (0.727) | −0.002 (0.022) | 0.93 |
| Hemoglobin A1c, % of total hemoglobin | 0.54 | 7 | 46 368 | 0.118 (0.072) | 0.186 (0.084) | 0.135 (0.390) | 0.003 (0.020) | 0.89 |
| Summary data A | 0.54 | 43 | 46 368 | 0.038 (0.063) | 0.086 (0.069) | 0.158 (0.242) | −0.002 (0.007) | 0.76 |

Abbreviations: HbA\(_{1c}\); hemoglobin A\(_{1c}\); MR, mendelian randomization; SNP, single-nucleotide polymorphism.

SI conversion factor: To convert glucose to mmol/L, multiply by 0.0555, HbA\(_{1c}\), to proportion of total hemoglobin, multiply by 0.01.

Results were standardized to a 1-SD decrease in birth weight due to genetic variants. For birth weight, 1-SD was assumed to correspond to 543 g, the pooled results from the Early Growth Genetics (EGG) Consortium.\(^23\) The Meta-analyses of Glucose and Insulin-Related Traits (MAGIC) Consortium did not report estimates of variants in units of standard deviations. β values from this consortium were standardized so that the association of birth weight with glycemic traits could be uniformly expressed in terms of standard deviations. For fasting glucose, 2-hour glucose, and HbA\(_{1c}\), from the MAGIC Consortium, 1SD was assumed to correspond to 13.1 mg/dL, 101 mg/dL, and 0.535%, respectively, the pooled SD of studies included in a previous report from the MAGIC Consortium.\(^18\) The threshold of significance was at the Bonferroni-adjusted level \(P < .01 (0.05/4 = 0.01)\).

Estimates of 7 SNPs for birth weight were extracted from EGG Consortium.\(^24\) For glycemic traits, estimates were derived from the MAGIC Consortium (n = 133 010 participants).\(^38\)\(^39\)\(^22\)

Estimates of 43 SNPs for birth weight were extracted from EGG Consortium.\(^35\) For glycemic traits, estimates were derived from the MAGIC Consortium (n = 133 010 participants).\(^39\)\(^22\)

d Two-hour glucose refers to measured blood glucose concentration 2 hours after consumption of dissolved glucose.
Our findings suggest that birth weight may be a useful target for a prevention strategy to mitigate T2D risk in later life. According to the thrifty phenotype hypothesis, the observed associations may originate in utero where intrauterine growth restriction affects epigenetic alterations and alters intracellular insulin-signaling pathways. Such permanent alterations in structure, physiology, and metabolism are thought to result in key disruptions to the endocrine system. It has been suggested that the public health implications of the inverse birth weight-T2D association depend on the precise nature of the underlying causal exposure and its amenability to change. Our MR results demonstrate that birth weight itself is a causal exposure, implying the public health impact of birth weight modification. Interestingly, previous interventions for increasing birth weight through changes in maternal nutrition have increased birth weight by up to 200 g in populations. Such an increase in birth weight could translate into a reduction in T2D risk of up to 10%. Therefore, our findings highlight the potential importance of improving fetal growth and nutrition in the prevention of T2D. In addition, ongoing research to understand the mechanistic links between the genetic loci that influence birth weight may lead to novel therapeutic strategies to modify birth weight and subsequently reduce the risk of T2D. Importantly, our findings are of public health significance and may help in understanding the mechanisms by which low birth weight increases risk of T2D.

The MR analysis used in this study satisfied 3 assumptions. Assumption 1 requires a strong link between the genetic variants used as an IV and birth weight. The GRS used in our study was demonstrated to be a strong IV with an F statistic greater than 18. For assumption 2, MR assumes the IV (GRS) was not associated with potential confounders. Study-level results showed that GRS was not associated with potential confounders; nevertheless, we could not exclude the possibility that our results might be affected by unmeasured confounders. For assumption 3, MR assumes that the IV for birth weight affects risk of T2D only through birth weight, but not through other pathways. To validate assumption 3, the intercept term estimated from MR-Egger regression was centered at the origin with a confidence interval including the null, suggesting that our results were not influenced by pleiotropy.

Our current study has several other strengths. First, to our knowledge, our study is the largest MR analysis assessing the association of birth weight with T2D risk and glycemic traits to date. The large sample size allowed us to assess the consistency of associations across studies and to gain sufficient power for conclusive estimation of associations. Second, sensitivity analyses of 2 different data sources (study-level and summary-level data sets) were conducted. The steps taken in this study reduced the risk of bias and pleiotropy. Importantly, the consistent associations estimated from complementary MR approaches, such as the weighted median regression method, inverse-variance-weighted method, and MR-Egger method, support the robustness of our findings. Finally, most of the studies included were homogeneous, and we used standardized methods and performed the analysis individually in each study. Therefore, the effect of population stratification on the instrumental results should be minimal.

Limitations
This study has some limitations, and the results should be interpreted with sufficient caution. Although the MR method is theoretically well established, we recognize that there are still many limitations in practice. First, we assumed that the associations of birth weight with T2D and glycemic traits were linear. Indeed, several observational studies suggested U-shaped associations. Therefore, further investigations employing a nonlinear MR approach are warranted to investigate the causality. In addition, we only used 7 SNPs in study-level analyses; this may lead to a weak IV, and thus introduce bias. Second, although the MR-Egger method suggested that our results were not affected by pleiotropy, it is possible that the shared genetic basis between birth weight and T2D may also contribute to the association. Third, although previous evidence indicated that variation in the fetal genome was the predominant driver of the birth weight associations, birth weight may be influenced by both fetal and correlated maternal genotypes.
approximately 0.5) between maternal and fetal genotype, we could not exclude the possibility that associations between fetal genotype and birth weight may result from indirect effects of the maternal genotype influencing birth weight via the intrauterine environment. In addition, recent GWAS identified several novel loci for offspring birth weight and highlighted maternal genetic effects that are independent of fetal genetics. Therefore, there are limitations in assuming causality on the basis of fetal genotype and fetal phenotype associations; dissecting maternal and fetal effects on adult T2D risk are also needed. In addition, maternal genetic variants could influence both offspring birth weight and other aspects of nurturing. Cross-generation MR studies are susceptible to such dynamic effects, which introduce potential biases. Therefore, future cross-generation MR studies should consider ways to reduce the biases that might result from these assumption violations.

Fourth, the widely used GRS may not fit the assumptions for an IV well. Furthermore, most of the risk factors are not static, but dynamic, and this may only be captured by taking both genetic and environmental factors into account over time. Fifth, assumption 3, that genetic markers affect T2D only through birth weight, is sometimes referred to as the exclusion restriction. The MR assumptions are violated if the genetic marker affects T2D through pathways other than through birth weight, which may lead to substantial biases in MR analysis. We cannot exclude the possibility that genetic markers for birth weight were associated with other pathways that influence T2D risk. In the present study, we used only the MR-Egger method to examine assumption 3. Although we found that the results were not influenced by pleiotropy, the MR-Egger analysis has limitations and is not able to reliably detect a dose-response relationship in the genetic associations with birth weight and with T2D, and hence cannot distinguish between pleiotropy and causal effect. Sixth, even though many relevant covariates, including age, sex, ethnicity, region, total energy, and PCA were included in the statistical models, residual and unmeasured confounding cannot be ruled out. Many established confounders, such as maternal diet, lifestyle, and additional genetic markers, may confound the association of birth weight with T2D risk. Further investigation considering these confounders is needed. In addition, given that the studies involved are overwhelmingly in non-Hispanic white populations, testing for generalizability to other ethnic groups warrants further investigation.

Conclusions
This study found that genetic predisposition to lower birth weight was associated with increased risk of T2D and impaired fasting glucose concentration. Our results suggest the presence of genetic effects on retarded fetal growth and increased diabetes risk that either are independent of each other or operate through alterations of integrated biological mechanisms.
Association of Birth Weight With Type 2 Diabetes and Glycemic Traits

R Study Group, Erasmus MC, University Medical Center Rotterdam, Rotterdam, Netherlands (Felix, Rivadeneira, Jaddoe); Department of Epidemiology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, Netherlands (Felix, Rivadeneira, Jaddoe); Department of Pediatrics, Erasmus MC, University Medical Center Rotterdam, Rotterdam, Netherlands (Felix, Jaddoe); Singapore Eye Research Institute, Singapore National Eye Centre, Singapore (Shi, Gupta, Saw, Zhao, Tham, B. Lim, S. H. Lim, Wong, Sabanayagam, Cheng); Department of Clinical Chemistry, Fimlab Laboratories, and Finnish Cardiovascular Research Center, Tampere, Finland (Lehtimäki); Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland (Lehtimäki); Division of Obstetrics and Gynaecology, School of Medicine, University of Western Australia, Crawley, Western Australia, Australia (C. A. Wang); Department of Obstetrics and Gynecology, School of Medicine and Public Health, The University of Newcastle, Callaghan, New South Wales, Australia (C. A. Wang); Ludwig-Maximilians-University of Munich, Dr von Hauner Children's Hospital, Division of Metabolic Diseases and Nutritional Medicine, Munich, Germany (Tiesler); Institute of Epidemiology, Helmholtz Zentrum München–German Research Center for Environmental Health, Neuherberg, Germany (Tiesler, Thiering, Standl); Division of Metabolic and Nutritional Medicine, Dr von Hauner Children’s Hospital, Klinikum der Universität Muenchen, Munich, Germany (Thiering, Rzehak, Grote, Koletzko); William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom (Marouli, Deloukas); MOE Key Lab of Environment and Health, School of Public Health, Tongji Medical College, Huazhong University of Science & Technology, Wuhan, Hubei, China (He, Yu, Wu); University of Lille Nord de France, Lille, France (Lecoeur, Frouguel); Institut Pasteur de Lille, Lille, France (Lecoeur, Frouguel); Department of Preventive Medicine and Public Health, University of Valencia, Valencia, Spain (Corella); CIBER Fisiopatología de la Obesidad y Nutrición, Instituto de Salud Carlos III, Madrid, Spain (Corella, Moreno, Coltell, Estruch); United States Department of Agriculture Research Service, Human Nutrition Research Center on Aging at Tufts University, Boston, Massachusetts (Lai, Ordovas); Growth Exercise, Nutrition and Development Research Group, Facultad de Ciencias de la Salud, Universidad de Zaragoza, Zaragoza, Spain (Moreno); Research Centre of Applied and Preventive Cardiovascular Medicine, University of Turku, Turku, Finland (Pitkänen, Raitakari, Pahkala); UCD Institute for Sport & Health, University College Dublin, Dublin, Ireland (Boreham); Department of Biostatistics, School of Public Health, Shandong University, Jinan, China (Zhang); Division of Preventive Medicine, Brigham & Women’s Hospital, Boston, Massachusetts (Ridker, Chasman); Department of Internal Medicine, Erasmus MC, University Medical Center, Rotterdam, Netherlands (Uitterlinden); Department of Epidemiology, Harvard School of Public Health, Boston, Massachusetts (Hofman, Chavarro); Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, Netherlands (Rosendaal, de Mutsert, Mook-Kanamori); Institute for Laboratory Medicine, University of Leipzig, Leipzig, Germany (Burkhardt, Thiery); Division of Cancer Control and Population Sciences, UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, Pennsylvania (Yuan); Department of Epidemiology, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, Pennsylvania (Yuan); Population, Policy and Practice, UCL Great Ormond Street Institute of Child Health, London, United Kingdom (Power, Hyppönen); Department of Public Health, Section of Epidemiology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark (Sørensen); MRC Integrative Epidemiology Unit & School of Social and Community Medicine, University of Bristol, Bristol, United Kingdom (Sørensen, Davey Smith); Danish Cancer Society Research Center, Copenhagen, Denmark (Tjønneland); Department of Public Health, Section for Epidemiology, Aarhus University, Aarhus, Denmark (Overvad); Aalborg University Hospital, Aalborg, Denmark (Overvad); Oxford NIHR Musculoskeletal Biomedical Research Unit, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, The Botnar Research Centre, University of Oxford, Oxford, United Kingdom (Cooper); Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts (Djousse, Chasman); Department of Internal Medicine, Erasmus MC, University Medical Center Rotterdam, Rotterdam, Netherlands (Rivadeneira); USC Office of Population Studies Foundation Inc, University of San Carlos, Cebu City, Philippines (Lee); Department of Anthropology, Sociology, and History, University of San Carlos, Cebu City, Philippines (Lee); Department of Clinical Physiology and Nuclear Medicine, Turku University Hospital, Turku, Finland (Raitakari); Department of Clinical Physiology, Tampere University Hospital, and Finnish Cardiovascular Research Center–Tampere, Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland (Kähönen); Division of Medicine, Turku University Hospital, Turku, Finland (Viikari); Department of Medicine, University of Turku, Turku, Finland (Viikari); Department of Paediatrics and NICU, CHC Site St-Vincent, Liége-Rocourt, Belgium (Langhendries); Paediatrics Research Unit, Universitat Rovira i Virgili, ISPV, Reus, Spain (Escribano); Department of Pediatrics, San Paolo Hospital, University of Milan, Milan, Italy (Verduci); Department of Nutrition and Dietetics, School of Health Science and Education, Harokopio University, Athens, Greece (Dedoussis); Department of Ophthalmology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore (B. Lim, Wong, Cheng); University of Lille Nord de France, Lille, France (Frouguel); INSERM, Centre for Research in Epidemiology and Population Health, Villejuif, France (Balkau); University Versailles Saint-Quentin-en-Yvelines, Versailles, France (Balkau); University Paris Sud 11, Villejuif, France (Balkau); Department of Computer Languages and Systems, University Jaume I, Castellon, Spain (Coltell); INSERM U1167, Institut Pasteur de Lille, University of Lille, Lille, France (Dallongeville, Meirhaeghe, Amouyel); INSERM U995, Hôpital Jeanne de Flandre,
Statistical analysis: Huang, Zheng, Ellervik, Li, Gao, Fang, Chai, Ahluwalia, Y. Wang, Voortman, Noordam, Frazier-Wood, Scholz, Sonestedt, Akiyama, Dorajoo, Zhou, Kölpeiläinen, Kleber, Crozier, Lemaître, Felix, Shi, Khor, C. A. Wang, Tiesler, Thiering, Standl, Rzehak, Marouli, He, Lecoeur, Corella, Lai, Pitkänen, Zhang, Graff, Lutterlinde, Kamatani, Rivadeneira, Jameson, Zhao, Grote, Yu, Froguel, Sevelsted, Coltell, Hyppönen, Meirhaeghe, Amouyel, Sim, Loeffler, Mook-Kanamori, Chasan.

Obtained funding: Khor, Corella, Moreno, Boreham, Saw, Ridker, Hofman, van Heemst, Rosendaal, de Mutsert, Yuan, Power, Tjànneland, Overvad, Raitakari, Coltell, Dallongeville, Niinikoski, Hyppönen, Määr, Insipk, Jaddoe, Mackey, Bännekylä, Estruch, Orho-Melander, Kubo, Mozaffarian, Psaty, Franco, Chasan, Qi.

Administrative, technical, or material support: Huang, T. Wang, Zheng, Noordam, Dorajoo, Gupta, Lehtimäki, Standl, He, Corella, Ridker, van Rooij, Rosendaal, Yuan, Hansen, Overvad, Raitakari, Kähönen, Tham, B. Lim, S. H. Lim, Balkau, Vinding, Bisgaard, Dallongeville, Pahikala, Määr, Jaddoe, Desso, Saba, Savanayagam, Bännelykke, Rossing, Estruch, Cheng, Teo, Koh, Kubo, Thiery, Psaty, Franco, North, Chavarro.

Supervision: Huang, Felix, Lehtimäki, Corella, Ridker, van Heemst, Rosendaal, de Mutsert, Sørensen, Cooper, Kähönen, Escrivano, Verduci, Bisgaard, Niinikoski, Hyppönen, Pedersen, Määr, Insipk, Wong, Mohlke, Mackey, Grusfeld, Deloukas, Bännekylä, Arnett, Sim, Teo, Kubo, Mook-Kanamori, Wu, North, Davey Smith, Qi.

Conflict of Interest Disclosures: Dr. Ellervik reported grants from the Region Zealand Foundation, Naestved Hospital Foundation, Johan and Lise Boserup Foundation, TrygFonden, Johannes F. Fog’s Foundation, Region Zealand, Naestved Hospital, Local Government Denmark Foundation, and The National Board of Health during the conduct of the study. Dr Scholz reported grants from Pfizer outside the submitted work. Dr Akiyama reported grants from the Japan Agency for Medical Research and Development (AMED) during the conduct of the study. Dr Kölpeiläinen reported grants from the Danish Council for Independent Research during the conduct of the study. Dr Godfrey reported grants from Nestec and grants from BenevolentAI outside the submitted work; in addition, Dr Godfrey had a patent to Phenotype prediction issued and a patent to Predictive use of CpG methylation issued. Dr Felix reported grants from European Union’s Horizon 2020 Research and Innovation Programme during the conduct of the study. Dr Ridker reported grants from Novartis, Kowa, and the National Heart, Lung, and Blood Institute; and personal fees from Inflazome, Corvidia, Civi Biopharm, Novartis, and Merck outside the submitted work. Dr van Heemst reported grants from the European Commission during the conduct of the study. Dr Kamatani reported grants from AMED during the conduct of the study and personal fees from Illumina outside the submitted work. Dr Yuan reported grants from the National Institutes of Health during the conduct of the study and grants from the National Institutes of Health outside the submitted work. Dr Cooper reported personal fees from Amgen during the conduct of the study and personal fees from Amgen outside the submitted work. Dr Verduci reported grants from the European Community during the conduct of the study. Dr Hyppönen reported grants from the National Health and Medical Research Council and Australian Research Council outside the submitted work. Dr Määr reported grants from Siemens Healthineers, Synlab Holding Deutschland GmbH, Bayer Vital GmbH, best hion dx GmbH, Boehringer Ingelheim, IMMundiagnostik GmbH, Merck Chemicals, Merck Sharp & Dohme, Novartis, Olink Proteomics, and AstraZeneca; and grants and personal fees from Aegeion Pharmaceuticals, AMGEN, Sanofi, Alexion Pharmaceuticals, BASF, Abbott Diagnostics, Numares, Berlin Chemie, and Alceza Therapeutics outside the submitted work. Dr Insipk reported grants and personal fees from the UK Medical Research Council during the conduct of the study. Dr Wong reported grants and personal fees from Allergan, Bayer, Boehringer-Ingelheim, Genentech, Merck, Novartis, OXurion, and Roche outside the submitted work; and serving as co-founder of Plano and EyRIS. Dr Deloukas reported grants from the British Heart Foundation and National Institute of Health Research UK during the conduct of the study. Dr Rossing reported grants from Novo Nordisk, Bayer, Astra Zeneca, Boehringer Ingelheim, Eli Lilly, Sanofi, and Gilead outside the submitted work. Dr Estruch reported grants from the Spanish Institute of Health, Fundacion Bosch i Gimpera, and Cereza y Salud; personal fees from Brewers of Europe, Fundacion Cereza y Salud, Instituto Cervantes, Pernaud Richart, and Wine and Culinary International Forum; and personal fees and grants from Fundacion Dieta Mediterranea; and non-financial support from ERA, and Sociedad Española de Nutrición during the conduct of the study; and grants from Laboratories Uriach, SEAT, Laboratories GrantFountain, and Ordesa outside the submitted work. Mr Amouyel reported personal fees from Servier and personal fees and grants from Genoscreen and Total Occupational Medicine outside the submitted work. Dr Mook-Kanamori reported part-time employment as a clinical research consultant for Metabolon, Inc. Dr Mozaffarian reported grants from the National Institutes of Health, Elsyium Health, Omada Health, DayTwo, UpToDate, and Gates Foundation; personal fees from GOED, Nutrition Impact, Pollock Communications, Bunge, Indigo Agriculture, Amarin, Acasta Pharma, Cleveland Clinic Foundation, America’s Test Kitchen, and Danone outside the submitted work. Dr Psaty reported serving on the Steering Committee of the Yale Open Data Access Project funded by Johnson & Johnson. No other disclosures were reported.

Additional Contributions: We thank the following individuals for their assistance with data collection and analysis: Ying Wu, PhD (University of North Carolina, Chapel Hill), Andrej Teren, PhD (University of Leipzig, Leipzig, Germany), Lavinia Paternoster, PhD (University of Bristol, Bristol, United Kingdom), Shu Pei Tan, MD (Singapore)
National Eye Center, Singapore), Craig E. Pennell, PhD (University of Western Australia), Linda S. Adair, PhD (University of North Carolina, Chapel Hill), Cornelia Enzenbach, PhD (University of Leipzig, Leipzig, Germany), Tine Marie Pedersen, PhD (University of Copenhagen, Copenhagen, Denmark), and Vera Mikkilä, PhD (Academy of Finland, Helsinki, Finland). They did not receive financial compensation.

REFERENCES

1. NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4.4 million participants. *Lancet*. 2016;387(10027):1513-1530. doi:10.1016/S0140-6736(16)00618-8

2. Hales CN, Barker DJ. Type 2 (non-insulin-dependent) diabetes mellitus: the thrifty phenotype hypothesis. *Diabetologia*. 1992;35(7):595-601. doi:10.1007/BF00400248

3. Whincup PH, Kaye SJ, Owen CG, et al. Birth weight and risk of type 2 diabetes: a systematic review. *JAMA*. 2008;300(24):2886-2897. doi:10.1001/jama.2008.886

4. Li Y, Ley SH, Tobias DK, et al. Birthweight and later life adherence to unhealthy lifestyles in predicting type 2 diabetes: prospective cohort study. *BMJ*. 2002;325(7360):359. doi:10.1136/bmj.325.7360.359

5. Davey Smith G, Hemani G. Mendelian randomization: genetic anchors for causal inference in epidemiological studies. *Hum Mol Genet*. 2014;23(R1):R89-R98. doi:10.1093/hmg/ddu328

6. Bowden J, Davey Smith G, Burgess S. Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression. *Int J Epidemiol*. 2015;44(2):512-525. doi:10.1093/ije/dyy080

7. Mahajan A, Go MJ, Zhang W, et al; DIAbetes Genetics Replication And Meta-analysis (DIAGRAM) Consortium; Asian Genetic Epidemiology Network Type 2 Diabetes (AGEN-T2D) Consortium; South Asian Type 2 Diabetes (SAT2D) Consortium; Mexican American Type 2 Diabetes (MAT2D) Consortium; Type 2 Diabetes Genetic Exploration by Next-Generation Sequencing in Multi-Ethnic Samples (T2D-GENES) Consortium. Genome-wide trans-ancestry meta-analysis provides insight into the genetic architecture of type 2 diabetes susceptibility. *Nat Genet*. 2014;46(3):234-244. doi:10.1038/ng.2897

8. Scott RA, Lagou V, Welch RP, et al; DIAbetes Genetics Replication and Meta-analysis (DIAGRAM) Consortium. Large-scale association analyses identify new loci influencing glycemic traits and provide insight into the underlying biological pathways. *Nat Genet*. 2012;44(9):991-1005. doi:10.1038/ng.2385
19. Strawbridge RJ, Dupuis J, Prokopenko I, et al; DIAGRAM Consortium; GIANT Consortium; MuTHER Consortium; CARDIoGRAM Consortium; C4D Consortium. Genome-wide association identifies nine common variants associated with fasting proinsulin levels and provides new insights into the pathophysiology of type 2 diabetes. *Diabetes*. 2011;60(10):2624-2634. doi:10.2337/db11-0415

20. Soranzo N, Sanna S, Wheeler E, et al; WTCCC. Common variants at 10 genomic loci influence hemoglobin A1C levels via glycemic and nonglycemic pathways. *Diabetes*. 2010;59(12):3229-3239. doi:10.2337/db10-0502

21. Saxena R, Hivert MF, Langenberg C, et al; GIANT Consortium; MAGIC Investigators. Genetic variation in GIPR influences the glucose and insulin responses to an oral glucose challenge. *Nat Genet*. 2010;42(2):142-148. doi:10.1038/ng.521

22. Dupuis J, Langenberg C, Prokopenko I, et al; DIAGRAM Consortium; GIANT Consortium; Global BPgen Consortium; Anders Hamsten on behalf of Prosarcis Consortium; MAGIC Investigators. New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk. *Nat Genet*. 2010;42(2):105-116. doi:10.1038/ng.520

23. Horikoshi M, Yaghootkar H, Mook-Kanamori DO, et al; Meta-Analyses of Glucose-and Insulin-related traits Consortium (MAGIC); Early Growth Genetics (EGG) Consortium. New loci associated with birth weight identify genetic links between intrauterine growth and adult height and metabolism. *Nat Genet*. 2013;45(1):76-82. doi:10.1038/nge.2017.247

24. Price AL, Patterson NJ, Plenge RM, Weinblatt ME, Shadick NA, Reich D. Principal components analysis corrects for stratification in genome-wide association studies. *Nat Genet*. 2006;38(8):904-909. doi:10.1038/ng1847

25. Burgess S, Thompson SG; CRP CHD Genetics Collaboration. Avoiding bias from weak instruments in mendelian randomization studies. *Int J Epidemiol*. 2011;40(3):755-764. doi:10.1093/ije/dyr036

26. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. *Stat Med*. 2002;21(11):1539-1558. doi:10.1002/sim.1186

27. Ioannidis JP, Patsopoulos NA, Evangelou E. Uncertainty in heterogeneity estimates in meta-analyses. *BMJ*. 2007;335(7626):914-916. doi:10.1136/bmj.39343.408449.80

28. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. *Stat Med*. 2002;21(11):1539-1558. doi:10.1002/sim.1186

29. Wald A. The fitting of straight lines if both variables are subject to error. *Ann Math Stat*. 1940;11:284-300. doi:10.1214/aoms/1177731868

30. Palmer TM, Sterne JA, Harbord RM, et al. Instrumental variable estimation of causal risk ratios and causal odds ratios in mendelian randomization analyses. *Am J Epidemiol*. 2011;173(12):1392-1403. doi:10.1093/aje/kwr026

31. Burgess S, Butterworth A, Thompson SG. Mendelian randomization analysis with multiple genetic variants using summarized data. *Genet Epidemiol*. 2013;37(7):658-665. doi:10.1002/gepi.21758

32. Yavorska OO, Burgess S. MendelianRandomization: an R package for performing mendelian randomization analyses using summarized data. *Int J Epidemiol*. 2017;46(6):1734-1739. doi:10.1093/ije/dyx034

33. Bowden J, Davey Smith G, Haycock PC, Burgess S. Consistent estimation in mendelian randomization with some invalid instruments using a weighted median estimator. *Genet Epidemiol*. 2016;40(4):304-314. doi:10.1002/gepi.21965

34. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. *BMJ*. 1997;315(7109):629-634. doi:10.1136/bmj.315.7109.629

35. Class QA, Rickert ME, Lichtenstein P, D’Onofrio BM. Birth weight, physical morbidity, and mortality: a population-based sibling-comparison study. *Am J Epidemiol*. 2014;179(5):550-558. doi:10.1093/aje/kwt304

36. de Lauzon-Guillain B, Balkau B, Charles MA, Romieu I, Boutron-Ruault MC, Clavel-Chapelon F. Birth weight, body silhouette over the life course, and incident diabetes in 91,453 middle-aged women from the French Etude Epidemiologique de Femmes de la Mutuelle Generale de l’Education Nationale (E3N) Cohort. *Diabetes Care*. 2010;33(2):298-303. doi:10.2337/dc09-1304

37. Jornayvaz FR, Vollenweider P, Bochud M, Mooser V, Waerber G, Marques-Vidal P. Low birth weight leads to obesity, diabetes and increased leptin levels in adults: the CoLaus study. *Cardiovasc Diabetol*. 2016;15(1):73. doi:10.1186/s12933-016-0389-2

38. Kaijser M, Bonamy AK, Akre O, et al. Perinatal risk factors for diabetes in later life. *Diabetes*. 2009;58(3):523-526. doi:10.2337/db08-0558

39. Ruiz-Narváez EA, Palmer JR, Gerlovin H, et al. Birth weight and risk of type 2 diabetes in the black women’s health study: does adult BMI play a mediating role? *Diabetes Care*. 2014;37(9):2572-2578. doi:10.2337/dc14-0731
40. Zimmermann E, Gamborg M, Sørensen TI, Baker JL. Sex differences in the association between birth weight and adult type 2 diabetes. Diabetes. 2015;64(12):4220-4225. doi:10.2337/db15-0494
41. Ross MG, Beall MH. Adult sequelae of intrauterine growth restriction. Semin Perinatol. 2008;32(3):213-218. doi:10.1053/j.semperi.2007.11.005
42. Godfrey KM, Barker DJ. Fetal nutrition and adult disease. Am J Clin Nutr. 2000;71(5(suppl):1345S-1352S. doi:10.1093/ajcn/71.5.1345s
43. Barker DJ, Thornburg KL. The obstetric origins of health for a lifetime. Clin Obstet Gynecol. 2013;56(3):511-519. doi:10.1097/GRF.0b013e31829cb9ca
44. Olsen SF, Halldorsson TI, Willett WC, et al; NUTRIX Consortium. Milk consumption during pregnancy is associated with increased infant size at birth: prospective cohort study. Am J Clin Nutr. 2007;86(4):1104-1110. doi:10.1093/ajcn/86.4.1104
45. Saad MJ, Carvalheira JB, Velloso LA. Birth weight and type 2 diabetes in adults. JAMA. 2009;301(15):1539. doi:10.1001/jama.2009.485
46. Dyck RF, Klomp H, Tan L. From “thrifty genotype” to “hefty fetal phenotype”: the relationship between high birthweight and diabetes in Saskatchewan Registered Indians. Can J Public Health. 2001;92(5):340-344.
47. McCance DR, Pettitt DJ, Hanson RL, Jacobsson LT, Knowler WC, Bennett PH. Birth weight and non-insulin dependent diabetes: thrifty genotype, thrifty phenotype, or surviving small baby genotype? BMJ. 1994;308(6934):942-945. doi:10.1136/bmj.308.6934.942
48. Rich-Edwards JW, Colditz GA, Stampfer MJ, et al. Birthweight and the risk for type 2 diabetes mellitus in adult women. Ann Intern Med. 1999;130(4, pt 1):278-284. doi:10.7326/0003-4819-130-4_Part_1-199902160-00005
49. Harder T, Rodekamp E, Schellong K, Dudenhausen JW, Plagemann A. Birth weight and subsequent risk of type 2 diabetes: a meta-analysis. Am J Epidemiol. 2007;165(8):849-857. doi:10.1093/aje/kwl071
50. Beaumont RN, Warrington NM, Cavadino A, et al; Early Growth Genetics (EGG) Consortium. Genome-wide association study of offspring birth weight in 86 577 women identifies five novel loci and highlights maternal genetic effects that are independent of fetal genetics. Hum Mol Genet. 2018;27(4):742-756. doi:10.1093/hmg/ddx429
51. Lawlor D, Richmond R, Warrington N, et al. Using mendelian randomization to determine causal effects of maternal pregnancy (intrauterine) exposures on offspring outcomes: sources of bias and methods for assessing them. Wellcome Open Res. 2017;2(11). doi:10.12688/wellcomeopenres.105671
52. VanderWeele TJ, Tchetgen EJ, Cornelis M, Kraft P. Methodological challenges in mendelian randomization. Epidemiology. 2014;25(3):427-435. doi:10.1097/EDE.0000000000000081
53. Burgess S, Thompson SG. Interpreting findings from mendelian randomization using the MR-Egger method. Eur J Epidemiol. 2017;32(5):377-389. doi:10.1007/s10654-017-0255-x

SUPPLEMENT.

Methods. Mendelian Randomization Method

Figure 1. Schematic Representation of a Mendelian Randomization Approach

Figure 2. Genetic Association With Birth Weight

Figure 3. Genetic Association With Risk of T2DM

Figure 4. Association of Birth Weight With Risk of T2DM

Figure 5. Causality Estimated From Individual Study

Table 1. Baseline Characteristics of Included 49 Studies in the CHARGE-BIG Study

Table 2. Assessment of Birth Weight and Covariates in the CHARGE-BIG Study

Table 3. Assessment of Type 2 Diabetes in the CHARGE-BIG Study

Table 4. Genotyping Information in the CHARGE-BIG Study

Table 5. Distribution of Genotypes of Included 7 SNPs in the CHARGE-BIG Study

Table 6. Associations Between Seven Loci Associated With Birth Weight and Various Anthropometric Measures Taken at Birth (Data From Summary Results)

Table 7. Genetic Association of Birth Weight Genetic Variants With Glycemic Traits (Data From Summary Results)

Table 8. Sixty Loci Associated With Birth Weight (P<5×10^-8) in European Ancestry and/or Trans-Ancestry (Data From Summary Results)

Table 9. Genetic Association of Birth Weight Related 60 Genetic Variants With Glycemic Traits (Data From Summary Results)

Table 10. Association of the Genetic Risk Score With Birth Weight and F Statistic for the Instrumental Variable in the NHS, HPFS, and WHI Cohorts
**eTable 11.** Association of Birth Weight Genetic Risk Score With Confounders According to Quartiles of the GRS in the NHS, HPFS and WHI Studies

eAppendix. Description of Included Studies
eReferences